The treatment outcome after ischemic heart disease is often not sufficient. Beyond the risk of death, a large group of patients who experience lasting disabling effects still remains. They perceive a major impact on quality of life and this often leads to social isolation, anxiety and depression due to a certain dependency on care providers.
Treatment with Cardiac Atrial Appendage Stem Cells (CASCs) can offer a solution to the adverse effects, since CASC technology is able to replace or repair the lost cardiomyocytes in the injured heart. This way, this technique not only helps with the resolution of physical discomfort, but also heals the specific cells of the heart muscle.
During animal research, our technique was found to have only low risks or side effects and the ejection fraction could be improved by 15%.
CASC8 aims to convert this technique from animal models to human use.
Who is involved?
CASC8 has an experienced team combining scientific, business and project management skills and experience.
Prof. Dr. med Marc Hendrikx
Prof. Dr. med Marc Hendrikx is a cardiothoracic surgeon who performed one of the first prospective randomized clinical trials, using autologous bone-marrow derived cells for the treatment of myocardial infarction in CABG patients. As a member of the Cardiology and Organ Systems research group (Uhasselt, Belgium), he focuses on in vitro and in vivo cellular and animal models in cardiovascular disease.